43 results about "Peritonitis" patented technology

The invention relates to the technical field of mRNA vaccines, and discloses a feline infectious peritonitis mRNA vaccine as well as a preparation method and application thereof. The feline infectious peritonitis mRNA vaccine comprises mRNA molecules; the mRNA molecule comprises an FIBV-S protein coding sequence as shown in SEQ ID NO: 6. According to the invention, the mRNA sequence for coding the natural FIBV-S protein is modified, so that the FIBV-S protein obtained by translation can be stably maintained at the prefusion conformation and has higher immunogenicity, thereby endowing the mRNA vaccine with a better immune effect and being beneficial to the prevention of feline infectious peritonitis.

The invention belongs to the technical field of biological medicine, and particularly relates to a nanometer antibody aiming at feline infectious peritonitis virus and application of the nanometer antibody. According to the invention, specific nano antibodies 2S-29 and 2S-39 of two novel FIPV S proteins are obtained by screening through a phage display technology, and a double-antibody sandwich ELISA method for detecting FIPV S antigens is provided. The two antibodies have excellent specificity and affinity to the feline infectious peritonitis virus FIPV S protein. A double-antibody sandwich ELISA method established based on the nano antibody has good specificity, repeatability and sensitivity, the lowest detection limit reaches 4 ng / mL, the FIPV S antigen can be rapidly and accurately detected, and a reliable means is provided for early diagnosis of feline infectious peritonitis.

The invention discloses a cat infectious peritonitis virus isolate and application thereof. The cat infectious peritonitis virus is separated from the peritoneal fluid of a 6-month-old female gradient silver cat, the preservation number of the cat infectious peritonitis virus is CGMCC (China General Microbiological Culture Collection Center) No.46420, and the name of the cat infectious peritonitis virus is SHAANXI-FIBV-II-2024. An animal model is successfully established by using the strain.

This invention provides a saRNA vaccine for the prevention of feline infectious peritonitis (FIP). The saRNA vaccine is a composition comprising saRNA A and saRNA B. The assembly elements of the saRNA include: a 5′ UTR, replicases nsp1-nsp4, a subgenomic promoter, a Kozak sequence, nucleic acid sequence A or nucleic acid sequence B, a 3′ UTR, and a polyadenylated tail (polyA). The saRNA vaccine provided by this invention is effective for the immunization prophylaxis of FIP types I and II. Furthermore, based on the development of this vaccine, by replacing the coding sequences of different antigens, it can be extended to the development of vaccines for other coronaviruses or other veterinary pathogens, demonstrating significant technological transfer value and industrialization prospects.

The utility model discloses a peritoneal dialysis catheter external tube air recognition automatic closing device, which relates to the technical field of medical instruments and comprises a packaging box, a box cover is arranged at the upper end of the packaging box, an external tube is fixedly connected to one side of the packaging box, an inner cylinder is arranged at the position, located in the packaging box, of the external tube, a mounting opening is formed in one side of the inner cylinder, and the outer tube is fixedly connected with the packaging box. A mounting opening is formed in the packaging box, a pressure sensor used for detecting the internal pressure of the inner barrel is mounted in the mounting opening, an electromagnetic valve is further mounted at the position, located in the packaging box, of the external connecting pipe, a microcontroller is arranged in the packaging box, and the electromagnetic valve and the pressure sensor are both electrically connected with the microcontroller. When the device works, once air is detected to enter, the device can automatically trigger a clamping mechanism to effectively prevent the air from entering the abdominal cavity, so that the risk of serious complications such as peritonitis and the like is remarkably reduced.

The invention discloses application of ailanone in preparation of a medicine for treating feline infectious peritonitis, and belongs to the field of biological medicine. The change of the expression quantity of the feline infectious peritonitis virus N protein is detected through indirect immunofluorescence and western blot, and the change of the quantity titer of the feline infectious peritonitis virus is detected through TCID50. Results show that ailanone has an obvious effect of resisting the feline infectious peritonitis virus, the inhibitory effect on the feline infectious peritonitis virus is enhanced along with increase of the drug concentration, and the half effective concentration is 0.09 mu M. Meanwhile, drug inhibition tests show that ailanone has no inhibition effect on feline calicivirus. The invention provides a novel therapeutic drug and strategy for treating feline infectious peritonitis.

The present application relates to the field of medical devices, and discloses a peritoneal dialysis patient peritonitis early warning device based on microfluidic technology, comprising a peritoneal dialysis external catheter and a microfluidic detection module; the peritoneal dialysis external catheter comprises a main passage for dialysis liquid infusion or dialysis waste liquid drainage, and a detection branch selectively communicated with the main passage; a flow path switching structure is arranged on the peritoneal dialysis external catheter, and the flow path switching structure is used for switching between a normal state and a detection state. In the present application, the detection branch selectively communicated with the main passage is arranged on the peritoneal dialysis external catheter, and the flow path switching structure is used for switching between the normal state and the detection state, so that the dialysis waste liquid can enter the microfluidic detection module for detection while maintaining the drainage of the main passage, in-situ detection is realized without changing the basic operation process of peritoneal dialysis, and good clinical process compatibility is achieved.

This invention provides a broad-spectrum mRNA vaccine for the prevention of feline infectious peritonitis (FIP) and its preparation method. The vaccine comprises mRNA molecule 1 and mRNA molecule 2. mRNA molecule 1 contains an LS-FIPV-I MEV-N-M antigen protein coding sequence composed of a self-assembled LS nanoparticle fusion sequence based on a tandem neutralizing epitope of the FIPV type I S protein and a T-cell epitope, as well as antigen-coding sequences of the N and M proteins. mRNA molecule 2 contains an antigen protein coding sequence of an LS nanoparticle structure self-assembled from the FIPV type II S protein receptor domain RBD. This invention, through the combination of two mRNA molecules, can achieve broad-spectrum protection against both FIPV types I and II while mitigating the risk of adverse drug reaction (ADE).

This invention discloses an automatic disinfection and connection device and method for peritoneal dialysis connectors. The device includes a housing containing a cap-pulling baffle, a hook, a cap-spinning baffle, a cap-removing assembly, a first clamping assembly, a multi-directional moving module, an iodine cap clamp, and a second clamping assembly. The housing also contains an ultraviolet disinfection assembly and a control circuit board. This automatic disinfection and connection device for peritoneal dialysis connectors improves the docking methods for double and short tubes, the cap removal method for silicone caps, and the loading and unloading method for iodine caps. It can automatically complete connector docking and separation operations, and can also automatically remove and replace iodine caps, greatly reducing manual operation, lowering the risk of infection caused by human intervention, reducing the occurrence of peritonitis, and improving the safety and standardization of patients' self-use of peritoneal dialysis connector connection devices.

The invention belongs to the fields of traditional Chinese medicines and proteins, provides application of Xiaochaihu decoction in preparation of a medicine for treating peritoneal dialysis related peritonitis, and identifies various antibacterial and immunomodulatory peptides from the Xiaochaihu decoction. The application proves that the common goldenrop decoction has a remarkable adjuvant therapy effect on peritoneal dialysis related peritonitis, and the antibacterial and immunomodulatory polypeptide identified on the basis has remarkable antibacterial and immunomodulatory activity, so that a good basis is provided for further development of medicines.

The application provides a joint conversion connecting device for peritoneal dialysis, and belongs to the technical field of medical equipment. The joint conversion connecting device for peritoneal dialysis comprises a pipeline assembly and a conversion assembly. The pipeline assembly comprises an external short pipe body, an iodophor cap body, a human body end joint body and a protective cover body. The surface of the external short pipe body is provided with a first fastening part. The end of the external short pipe body is provided with a first threaded connector. The surface of the iodophor cap body is provided with a second fastening part. The connecting end of the iodophor cap body is provided with a first groove. The joint in the closed shell is automatically switched and screwed. The joint connecting part does not need to be contacted by hands in the whole process. The peritonitis infection risk in the peritoneal dialysis liquid replacement process is greatly reduced. The external short pipe body, the iodophor cap body and the human body end joint body of the pipeline assembly all adopt the clinical general screw thread interface standard. A special dialysis liquid joint is not needed. The adaptability is strong. The defect that the generality of the prior art is poor is solved.

This application provides a selective HDAC6 inhibitor, its preparation method, and its application, belonging to the field of medicinal chemistry. The selective HDAC6 inhibitor is a compound of Formula I or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, and L are as described herein. The compound of Formula I is a highly selective histone deacetylase 6 (HDAC6) inhibitor, which can be used for diseases caused by HDAC6 abnormalities, such as inflammatory diseases (e.g., peritonitis, inflammatory bowel disease, psoriasis) and other diseases.

Provided is a pharmaceutical preparation, the pharmaceutical preparation comprising: a nucleic acid fragment, the nucleic acid fragment being mRNA, the nucleic acid fragment comprising at least one of a first nucleic acid fragment, a second nucleic acid fragment and a third nucleic acid fragment; the first nucleic acid fragment encodes M protein of feline infectious peritonitis virus; the second nucleic acid fragment encodes N protein of feline infectious peritonitis virus; the third nucleic acid fragment encodes S, Sec or SII protein of the feline infectious peritonitis virus; the first nucleic acid fragment, the second nucleic acid fragment and the third nucleic acid fragment are connected or not connected.

The peritoneal dialysis catheter protective sleeve comprises a flexible sleeve, a first opening and a second opening are formed in the two ends of the flexible sleeve in the length direction of the flexible sleeve respectively, a notch extending in the length direction of the sleeve is formed in the peripheral wall of the sleeve, and the sleeve can deform to expand the notch. The first opening is used for allowing the dialysis catheter to penetrate through, the second opening is used for allowing the titanium connector to penetrate through, a positioning groove is formed in the inner circumferential wall of the second opening, and the positioning groove is used for being matched with a concave part of an external short pipe. According to the peritoneal dialysis catheter, it can be guaranteed that the joint of the titanium connector and the peritoneal dialysis catheter is not prone to being folded and bent, abrasion of the titanium connector and the peritoneal dialysis catheter is prevented, and therefore the peritoneal dialysis catheter is protected against breakage and seepage, and peritonitis is avoided. Meanwhile, the positioning groove is matched with the concave part of the external short pipe, so that the external short pipe can be protected from falling off due to various accidents to a certain extent.

The invention relates to the technical field of veterinary drugs, and particularly provides a polynucleotide molecule composition for preventing cat infectious peritonitis, a chimeric polynucleotide molecule and an mRNA vaccine. In order to overcome the ADE effect caused by S protein full-length antigen in the prior art, FIPV N protein without ADE risk is adopted and is combined with screened S protein specific T cell and B cell epitopes. Core schemes include two classes: one is a separate polynucleotide composition comprising epitope peptides encoding N and S proteins; and 2, a single chimeric polynucleotide encoding N protein and S protein epitope peptides. The polynucleotides are optimized by codons and encapsulated in lipid nanoparticles (LNP) to prepare vaccines. Experiments prove that the vaccine can synergistically stimulate powerful immune response, the survival rate of immune cats is remarkably increased to 80%-100% from standard 40% on the premise that ADE is not caused, and FIP is effectively prevented.

The present invention provides a system and a method for monitoring Peritoneal dialysis (PD) effluent to determine peritonitis condition using a machine learning model. The system comprises a user input device configured to upload at least one image of the peritoneal dialysis (PD) effluent bag and an image processing server having a processor configured to receive at least one image from the input device, process the received image of the PD effluent bag, by a convolutional neural network (CNN) model and classify the processed received image in one or more category of infection levels. The system further comprises an output device coupled to the image processing server and is configured to output the category of an infection level based on the processing of the image from the input device. Further, the processor is configured to create a training dataset from a plurality of images of the peritoneal dialysis (PD) effluent bag having an effluent density with varying colour gradient, train the convolutional neural network (CNN) model, with the plurality of the images of the PD effluent bag and classify the images of the PD effluent, with one or more category of the infection level.

The invention discloses a peritoneal dialysis related peritonitis patient treatment failure risk prediction method, and relates to the technical field of intelligent medical information processing, and the method comprises the steps: carrying out the key feature screening based on a patient standardized spatio-temporal feature vector set, simulating the evolution trajectory under different clinical conditions through an anti-fact sample, and carrying out the prediction of the treatment failure risk of a peritoneal dialysis related peritonitis patient. Generating an anti-fact disease course evolution trajectory data set; performing feature fusion on the anti-fact disease course evolution trajectory data set and multi-source clinical data by adopting time window splicing and multi-dimensional alignment to form a three-dimensional fusion feature tensor with a time dimension, a feature dimension and a scene dimension; carrying out entropy risk assessment by using the three-dimensional fusion feature tensor, and obtaining a dynamic treatment failure risk value; and carrying out risk state division according to the dynamic treatment failure risk value, and generating an individualized risk prediction result and an intervention prompt. According to the method, the complexity and uncertainty of the course of disease are effectively quantified, and dynamic and accurate risk early warning and decision support are provided for clinic.

This disclosure relates to the development of a multi-antigen mRNA vaccine against feline infectious peritonitis virus (FIPV). Provided is a pharmaceutical formulation. The pharmaceutical formulation includes a nucleic acid fragment. The nucleic acid fragment is mRNA and includes at least one of a first nucleic acid fragment, a second nucleic acid fragment, or a third nucleic acid fragment. The first nucleic acid fragment encodes an M protein of feline infectious peritonitis virus; the second nucleic acid fragment encodes an N protein of feline infectious peritonitis virus; the third nucleic acid fragment encodes an S protein, an S_ec protein, or an SII protein of feline infectious peritonitis virus; and the first nucleic acid fragment, the second nucleic acid fragment, and the third nucleic acid fragment are linked or not linked.

The invention relates to the technical field of medical monitoring, and discloses an artificial intelligence peritonitis monitoring device, system and method, and the device comprises a closed darkroom, a high-transparency pipeline, a simulated natural light source, a color sensor, a parallel light source, a light sensor, an opaque partition plate and an intelligent chip; the closed darkroom is divided into an upper color monitoring area and a lower turbidity monitoring area through a non-transparent partition plate, and the high-transparency pipeline vertically penetrates through the non-transparent partition plate and is communicated with the drainage end of the peritoneal dialysis pipeline and a waste liquid barrel; the intelligent chip is connected with the color sensor and the light sensor, an artificial intelligence algorithm is built in the intelligent chip, the intelligent chip carries out noise suppression by constructing a four-dimensional Kalman filtering state vector containing RGB three-primary color components and turbidity, peritonitis risk judgment is carried out based on fusion data of dialysate optical characteristics and patient information, and the peritonitis risk judgment result is obtained. Peritonitis recognition sensitivity is not less than 95%, specificity is not less than 99%, and accuracy is not less than 98%; the problem of single detection dimension is solved, and accurate support is provided for early warning.

The invention discloses a recombinant feline infectious peritonitis double-layer vesicle tracer virus as well as a construction method and application thereof, and belongs to the technical field of bioengineering. A CRISPR / Cas9 mediated homologous recombination technology is used, on the basis of a reverse genetic manipulation platform, an Nsp3 region of plasmid pBAC-FIBV-791146 is replaced with a reporter gene sequence, then the feline infectious peritonitis virus is rescued, and the recombinant feline infectious peritonitis bilayer vesicle tracer virus is formed. The biological characteristics of the strain and the tracing effect of the double-membrane vesicles are measured, it is proved that insertion of the ZsGreen gene does not affect virus proliferation, but the recombinant virus has the characteristic of tracing the double-membrane vesicles, and the recombinant virus can serve as a research tool for monitoring the forming mechanism of the double-membrane vesicles and a drug screening tool for resisting the feline infectious peritonitis virus.

The embodiment of the application discloses a natural small molecule inhibitor targeting NLRP3 inflammasome and application thereof, and belongs to the technical field of biological medicine. Chuanxiongdiolide R11 is a phthalide dimer compound with clear stereochemistry found in traditional Chinese medicine Chuanxiong, which can target NLRP3 inflammasome, prevent the activation and assembly of the inflammasome, thereby inhibiting caspase-1 activation, GSDMD cleavage, pyroptosis and the maturation and release of IL-1beta / IL-18. The compound can be used for preparing a drug for treating NLRP3 related inflammatory diseases such as systemic inflammation and peritonitis, and has a good clinical application prospect, and provides a new idea for developing and applying NLRP3 inhibitors in clinic.

The invention discloses automatic disinfection and connection equipment and an automatic disinfection and connection method for a peritoneal dialysis connector. The automatic disinfection and connection equipment comprises an equipment shell, and the equipment shell is internally provided with a blind nut baffle, a drag hook, a turncap baffle, a cap removing assembly, a first clamping assembly, a multi-directional moving module, an iodophor cap chuck, a second clamping assembly and the like; an ultraviolet disinfection assembly, a control circuit board and the like are further arranged in the equipment shell. According to the automatic disinfection connecting equipment for the peritoneal dialysis connector, the butt joint mode of the duplex tube and the short tube, the uncapping mode of the silica gel cap and the loading and unloading mode of the iodophor cap are improved, so that the butt joint and separation operation of the connector can be automatically completed, the cap can be automatically uncapped and the iodophor cap can be automatically replaced, the manual operation is greatly reduced, and the working efficiency is improved. The infection risk caused by human intervention is reduced, peritonitis is reduced, and the safety and the standardization of the peritoneal dialysis connector connecting equipment used by a patient by himself / herself are improved.

Peritonitis sensors, including peritonitis sensors for automated peritoneal dialysis (APD) systems, and associated systems, devices, and methods are disclosed herein. In one embodiment, an APD system includes a disposable set, a portion of which is at least partially aligned with a peritonitis sensor. The peritonitis sensor can be configured to capture one or more peritonitis measurements from the solution in the disposable set. The APD system can determine whether one or more peritonitis measurements indicate the presence of peritonitis in a patient from which the solution is drained. In some embodiments, if the APD system determines that one or more peritonitis measurements indicate peritonitis, the APD system can alert a user of the system to the presence of peritonitis in the patient.

The present teachings include optical systems and methods for detection of peritonitis in early stages for patients undergoing a peritoneal dialysis (PD) treatment. An initial measurement of optical extinction of effluent fluid may be stored as a baseline value for a patient, e.g., to compensate for color, density, and similar optical factors related to the specific patient's physiology. Optical extinction through the effluent may be periodically measured over the course of a PD treatment, and extinction of signal relative to the baseline is analyzed, primarily for early indicators of potential peritonitis. The system may be externally connected to an effluent conduit, e.g., via a clip. A technique of ratioing an optical signal through effluent to a reference optical signal for measurements may provide high sensitivity while filtering out significant noise, enabling early detection of infection. Alerts of potential infection may be provided to the patient, caregiver, and / or medical team.

The invention relates to a kit for feline infectious peritonitis virus and application of the kit, and relates to the field of detection of feline infectious peritonitis virus. The kit comprises an amplification system, a detection system and a detection card, the amplification system is used for amplifying a target sequence, the target sequence is selected from SEQ ID NO.1, the amplification system comprises a primer group, the primer group comprises an upstream primer and a downstream primer, the upstream primer is as shown in SEQ ID NO.2, and the downstream primer is as shown in SEQ ID NO.8. The amplification system of the kit can specifically amplify the target sequence of the feline infectious peritonitis virus, can distinguish the feline infectious peritonitis virus from other viruses, and does not have cross reaction with other viruses.

The application relates to a cat infectious peritonitis virus S protein receptor binding region monoclonal antibody and application thereof, relates to the technical field of biology, and aims to provide a cat infectious peritonitis virus S protein receptor binding region monoclonal antibody and application thereof.The amino acid sequence of a heavy chain variable region of the monoclonal antibody is shown in a sequence table SEQ ID NO.1, and the amino acid sequence of a light chain variable region is shown in a sequence table SEQ ID NO.2.The application adopts Western blot and IFA methods to identify the reactivity of MAb, and identifies an antigen epitope recognized by MAb.The antigen epitope is conservative in type I cat coronavirus, which indicates that the monoclonal antibody can recognize various type I FCoV strains, has broad spectrum, and is not accidentally directed to a single strain.The antigen epitope has no cross reaction with type II, which indicates that the specificity is high, can be used for distinguishing type I and type II infections, and has diagnostic application value.

The present application belongs to the technical field of animal medicine, and particularly relates to an immune response modulator based on a chlorine dioxide chelate as well as a preparation method and application thereof. The present application proposes an innovative immune response modulator for effectively treating feline infectious peritonitis. The immune response modulator is prepared by mixing chlorine dioxide with a chelating agent to react and prepare a chlorine dioxide chelate, and then combining the chelate with an immune boosting component and a stabilizer to obtain the immune response modulator with significant curative effect. Through the chelation technology, the toxicity of chlorine dioxide is effectively reduced, thereby reducing the potential harm to the cat body. Meanwhile, the combination of the chlorine dioxide chelate and the immune boosting component can synergistically improve the cellular immunity and humoral immunity response of the cat and enhance the defense capability of the immune system against viruses, thereby effectively improving the treatment effect of feline infectious peritonitis.

The invention provides a method for constructing circular RNA (Ribonucleic Acid) and a vaccine aiming at the cat FIPV. The method relates to a pharmaceutical preparation, the pharmaceutical preparation comprises nucleic acid fragments, the nucleic acid fragments are circular RNA, and the nucleic acid fragments comprise a first nucleic acid fragment and a second nucleic acid fragment; the first nucleic acid fragment encodes M protein of feline infectious peritonitis virus; the second nucleic acid fragment encodes N protein of feline infectious peritonitis virus; the first nucleic acid fragment and the second nucleic acid fragment are connected or not connected.

The invention discloses a nucleoside prodrug and application thereof in treating feline infectious peritonitis, and belongs to the field of medicinal chemistry. The invention provides a compound as shown in the specification or pharmaceutically acceptable salt thereof, the compound provided by the invention can effectively inhibit feline infectious peritonitis virus (FIPV), the antiviral activity of the compound obviously exceeds that of GS-441524, and meanwhile, the compound has good pharmacokinetic properties, high bioavailability and good solubility, and can be applied to preparation of drugs for treating feline infectious peritonitis virus (FIPV) or other drugs for treating feline infectious peritonitis virus (FIPV) or other drugs for treating feline infectious peritonitis virus (FIPV). The preparation is simple, the synthesis is easy, and large-scale industrial production can be realized.

The invention provides a broad-spectrum mRNA vaccine for preventing feline infectious peritonitis and a preparation method thereof, the vaccine comprises an mRNA molecule 1 and an mRNA molecule 2, the mRNA molecule 1 comprises a self-assembled LS nanoparticle fusion sequence based on a neutralizing epitope of series FIPV type I S protein and a T cell epitope, and the mRNA molecule 2 comprises a self-assembled LS nanoparticle fusion sequence based on series FIPV type I S protein. The LS-FIBV-I MEV-N-M antigen protein coding sequence is composed of the antigen coding sequences of the N protein and the M protein; the mRNA molecule 2 comprises an antigen protein coding sequence which is fused and self-assembled by an FIPV II type S protein receptor structural domain RBD and has an LS nano-particle structure. According to the invention, through the combination of double mRNA molecules, while the ADE risk is avoided, the broad-spectrum protection of the FIPV type I and the FIPV type II is realized.